- Posted August 6, 2013 by Irl B. Hirsch, MDOver the past six months we have had more questions than answers about the risk of incretin therapy (DPP-4 inhibitors and GLP-1 agonists) and the increased risks for both pancreatitis and pancreatic carcinoma. The discussion seems to have resolved to an interim and perhaps temporary conclusion based on the recent American Diabetes Association Scientific Sessions in Chicago in June.At that conference Dr.
- Posted July 25, 2013 by Doron Schneider, MD, FACP
- Posted June 25, 2013 by Joseph Largay, PA-C, CDE
With all the things I have to cover during my 20 minute follow-up visits with my patients with diabetes, I sometimes struggle with whether or not to interrupt as they tell me about something that, at first, seems irrelevant, at least to me.
I do, however, enjoy most of these discussions as I learn about their recent to Hawaii or some fishing trip. I do enjoy living vicariously through the lives of my patients!
- Posted May 29, 2013 by John L. Leahy, MD
Dr. Jack Leahy, endocrinologist and general internist, Dr. Doron Schneider, weigh different initial treatment options presented by leading endocrinologists Silvio Inzucchi, MD, Alan J. Garber, MD and Laurence Kennedy, MD
- Posted January 17, 2013 by John L. Leahy, MD(Full disclosure – I am an Advisor to Janssen pharmaceuticals that makes canagliflozin)An FDA advisory panel last week reviewed canagliflozin, with the majority recommending approval. Canaglifozin is the first member of a new class of oral medications for type 2 diabetes–sodium-glucose co-transportor-2 (SGLT2) inhibitors–that will likely make it to the U.S. market.
- Posted January 17, 2013 by Irl B. Hirsch, MDDr. Leahy’s comments are right-on target. Some further observations by another endocrinologist who can’t determine who the best patient for this new class of drugs will be:1. The advisory committee had problems with the bump in LDL-cholesterol. True, this is a surrogate, not a true “outcome” that will be determined in the CANVAS study. But do you recall the last time we had this debate with a diabetes drug?
- Posted September 6, 2012 by Doron Schneider, MD, FACP
Dr. Doron Schneider, general internist, and Dr. Jack Leahy, endocrinologist, discuss intensifying therapy on a patient who is on two agents with A1C greater than 8.5.
The Good, The Bad, and the Ugly Part II: Why I’m not a Fan of the ADA/EASD’s 2012 Position StatementPosted June 6, 2012 by John L. Leahy, MD
- Page 1 of 3